Market Overview

Vertex Announces Oral Selective JAK3 Inhibitor VX-509 Shows Statistically Significant Improvement in RA Phase 2b Study

Vertex
Pharmaceuticals (NASDAQ: VRTX) today announced 12-week
results from an ongoing Phase 2b study of VX-509, an investigational
oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice
daily in people with active rheumatoid arthritis (RA) taking
methotrexate. The study met its primary endpoints of both the proportion
of people who achieved at least a 20 percent improvement in signs and
symptoms of RA, as measured by the ACR improvement criteria (ACR20), and
the change from baseline in Disease Activity Score for 28 joints
(DAS28). All doses of VX-509 showed statistically significant ACR20 and
ACR50 responses versus placebo and statistically significant improvement
from baseline in DAS28 versus placebo. The three highest dose groups
showed

See full press release

Posted-In: Earnings News Guidance Contracts Buybacks FDA Legal Management

 

Most Popular

Related Articles (VRTX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters